Safety of double-dose transdermal scopolamine

Pharmacotherapy

Volumn 29, Issue 9, 2009, Pages 1082-1088

  Bar, Ronen ^a   Gil, Amnon ^a   Tal, Dror ^a  

^a ISRAEL NAVAL MEDICAL INSTITUTE   (Israel)

Author keywords

Adverse effects; Double dose; Plasma levels; Transdermal scopolamine

Indexed keywords

PLACEBO; SCOPOLAMINE;

ADULT; ARTICLE; BLOOD PRESSURE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; HEART RATE; HUMAN; MALE; MOTION SICKNESS; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL PATCH; VISION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; ISRAEL; MALE; MILITARY PERSONNEL; MOTION SICKNESS; QUESTIONNAIRES; SCOPOLAMINE; YOUNG ADULT;

EID: 69249088586     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.9.1082     Document Type: Article

References (29)

1. Reason JT, Brand JJ. Motion sickness. London: Academic Press, 1975.
2. Griffin MJ. Handbook of human vibration. London: Academic Press, 1990:271-332.
3. Nachum Z, Shupak A, Gordon CR. Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2006;45:543-566 (Pubitemid 44046484)
4. Spinks A, Wasiak J, Villanueva E, Bernath V. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2007;(3):CD002851. (Pubitemid 351805650)
5. Clissold SP, Heel RC. Transdermal hyoscine (scopolamine): a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985;29:189-207. (Pubitemid 15144747)
6. Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G. Transdermal scopolamine in the prevention of motion sickness at sea. Clin Pharmacol Ther 1981;29:414-419 (Pubitemid 11134121)
7. Pyykko I, Schalen L, Jantti V. Transdermally administered scopolamine vs dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness. Acta Otolaryngol 1985;99:588-596
8. Gil A, Nachum Z, Dachir S, et al. Scopolamine patch to prevent seasickness: clinical response vs plasma concentration in sailors. Aviat Space Environ Med 2005;76:766-770 (Pubitemid 41076393)
9. Attias J, Gordon C, Ribak J, Binah O, Rolnick A. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea. Aviat Space Environ Med 1987;58:60-62 (Pubitemid 17002953)
10. Price N, Schmitt LG, Shaw JE. Transdermal delivery of scopolamine for prevention of motion-induced nausea in rough seas. Clin Ther 1979;2:258-262 (Pubitemid 10170453)
11. Noy S, Shapira S, Zilbiger A, Ribak J. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo: a comparative study at sea. Aviat Space Environ Med 1984;55:1051-1054 (Pubitemid 15221394)
12. Doweck I, Dachir S, Spitzer O, et al. Rate of absorption of scopolamine after application of Scopoderm-TTS [abstract]. Aviat Space Environ Med 1995;66:467.
13. Nachum Z, Shahal B, Shupak A, et al. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001;296:121-123 (Pubitemid 32015069)
14. Shaw JE, Schmitt LG, McCauley ME, Royal JW. Transdermally administered scopolamine for prevention of motion sickness in a vertical oscillator [abstract]. Clin Pharmacol Ther 1977;21:117.
15. Cintron NM, Chen YM. A sensitive radioreceptor assay for determining scopolamine concentrations in plasma and urine. J Pharm Sci 1987;76:328-332
16. Muir C, Metcalfe R. A comparison of plasma levels of hyoscine after oral and transdermal administration. J Pharm Biomed Anal 1983;1:363-367 (Pubitemid 14153089)
17. Ensing K, de Zeeuw RA, Ensing GJ. Pharmacokinetics of free and glucuronidated scopolamine following transdermal delivery of scopolamine in children [abstract]. Acta Pharmacol Toxicol Copenh 1986;59(suppl 5):81.
18. Graybiel A, Knepton J, Shaw J. Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat Space Environ Med 1976;47:1096-1100
19. Graybiel A, Cramer DB, Wood CD. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat Space Environ Med 1982;53:770-772 (Pubitemid 12017892)
20. Shaw JE, Urquhart J. Transdermal drug administration: a nuisance becomes an opportunity [editorial]. Br Med J 1981;283:875-876 (Pubitemid 11000242)
21. Shaw JE, Chandrasekaran SK. Transdermal therapeutic systems. In: Prescott LF, Nimmo WS, eds. Drug absorption. The proceedings of the international conference on drug absorption, Edinburgh, September, 1979. New York: ADIS Press, 1981:186-193
22. Scheurlen M, Bittiger H, Ammann B. Simple radioligand binding assay for the determination of urinary scopolamine. J Pharm Sci 1984;73:561-563 (Pubitemid 14134341)
23. Shaw JE, Chandrasekaran SK, Taskovich L. Use of percutaneous absorption for systemic administration of drugs. Pharm J 1975;215:325-328
24. Fee WE Jr, Vierra V. The effect of transdermal therapeutic system-scopolamine in controlling acute vertigo [abstract]. Otolaryngol Head Neck Surg 1979;87(4, section 2):240. (Pubitemid 10250977)
25. Parrott AC. Transdermal scopolamine: effects upon psychological performance and visual functioning at sea. Hum Psychopharmacol 1988;3:119-125
26. Parrott AC. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med 1989;60:1-9.
27. Gordon C, Binah O, Attias J, Rolnick A. Transdermal scopolamine: human performance and side effects. Aviat Space Environ Med 1986;57:236-240 (Pubitemid 16157763)
28. Gonen A, Gordon CR, Spitzer O, Shahal B, Shupak A. Comparison of performance under the influence of three antimotion sickness drugs [abstract]. Aviat Space Environ Med 1998;69:209.
29. Ferris FD, Kerr IG, Sone M, Marcuzzi M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom Manage 1991;6:389-393